Reply to "Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185."

Susanna Burckhardt

doi:10.3390/ijms18010122

Abstract

n/a.

Highlights

Thank you providing the opportunity to reply to the Comment on our recent paper
Strom and Andreasen, who are employees of Pharmacosmos, a Danish-based pharmaceutical company that commercializes iron dextran and iron isomaltoside 1000, criticize our work as it cannot be directly extrapolated to the clinical setting
In order to make sure that the results were unbiased, the ELISA experiments were carried out by GenScript with blinded samples

Summary

Introduction

Strom and Andreasen, who are employees of Pharmacosmos, a Danish-based pharmaceutical company that commercializes iron dextran and iron isomaltoside 1000, criticize our work as it cannot be directly extrapolated to the clinical setting. In response to Strom and Andreasen, I would like to state that, as clearly mentioned in the introduction, the experiments described in Neiser et al. [1] were triggered by the criticism [2] of our previous work published in 2011 [3].

Results

Conclusion